Sino Biopharmaceutical Gains NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes
Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that...
Product approvals
Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval
Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...
Jiangsu Simcere Pharmaceutical Wins NMPA Nod for Biosimilar Version of Erbitux
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), a Chinese pharmaceutical company, has announced that it...
J&J’s Tecvayli Earns NMPA Approval for Relapsed or Refractory Multiple Myeloma
Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S. healthcare company, has announced that it...
Hybio Pharmaceutical’s Biosimilar Liraglutide Gets Temporary FDA Nod Pending Patent Expiry
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...
Shanghai Haihe Pharmaceutical’s Glumetinib Earns Marketing Approval in Japan for NSCLC Treatment
Shanghai Haihe Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, has announced that it has received...
Haisco Pharmaceutical Gets NMPA Green Light for Cofrogliptin to Treat Type 2 Diabetes
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...
Novo Nordisk’s Once-Weekly Insulin Awiqli Approved by China’s NMPA for Type 2 Diabetes
The National Medical Products Administration (NMPA) has granted market approval for Awiqli (insulin icodec), a...
Takeda’s Fruquintinib for Metastatic Colorectal Cancer Receives European Commission Marketing Approval
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its partner Takeda (TYO: 4502,...
Zai Lab’s Partner Argenx Receives FDA Approval for CIDP Treatment Vygart Hytrulo
Argenx SE (NASDAQ: ARGX), the U.S. partner of China-based biopharmaceutical company Zai Lab Ltd (NASDAQ:...
Qilu Pharmaceutical’s Generic Version of Vyndaqel Receives NMPA Marketing Approval
The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic version...
Luye Pharma’s Once-Weekly Parkinson’s Disease Treatment Receives NMPA Approval
Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from the...
Dizal Pharmaceutical’s Golidocitinib Wins NMPA Approval for Relapsed/Refractory PTCL
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China established in 2017, has...
AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio
AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved...
Hybribio Ltd Secures NMPA Approval for α-Thalassemia Genotyping Detection Kit
Hybribio Ltd (SHE: 300639), a Guangdong-based provider of nucleic acid molecular diagnostic products, has announced...
Kanghong Pharmaceutical’s Lumitin Approved in Myanmar for Neovascular AMD Treatment
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...
China Medical System’s Methylthioninium Tablets Get NMPA Green Light for Colonoscopy Use
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received New Drug...
MSD’s Capvaxive Vaccine Targets 21 Serotypes of Streptococcus Pneumoniae
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced...
Envonalkib, Chia Tai Tianqing’s Next-Gen ALK Inhibitor, Wins NMPA Approval for Untreated ALK+ NSCLC
Chia Tai Tianqing’s next-generation ALK inhibitor, envonalkib, has received approval from the National Medical Products...
Nanjing Sanhome’s Oritinib Wins NMPA Approval for EGFR T790M Positive NSCLC
Nanjing Sanhome Pharmaceutical Co., Ltd has received approval from the National Medical Products Administration (NMPA)...